Advancing the Science of Radiopharmaceuticals Conjugations Radiolabeling Research & 

Advancing the
Science of Radiopharmaceuticals
Conjugations Radiolabeling Research & 


Years Combined

Who We Are

Your Partner -
Proposal to Product

IsoTherapeutics Group, LLC (IsoTherapeutics) is a radiopharmaceutical company that was founded in 2005 by two entrepreneur scientists with a passion for advancing the technology of radiopharmaceuticals. The company scientists, while employed at the Dow Chemical Company, developed QUADRAMET® a radiopharmaceutical for treatment of bone pain due to metastatic cancer, treatments for arthritis, osteoporosis, and osteomyelitis, just to name a few. IsoTherapeutics scientists have received over 100 patents for developing chemistry and radiopharmaceutical formulations.

Our Services

IsoTherapeutics offers host of services to the pharmaceutical and life-science industries.

The range of services include helping customers/partners with early stage research from proof of concept for a new chemistry or drug molecule through making of the drug in a cGMP facility for preclinical studies. These services include:

State of the Art


IsoTherapeutics Group is located about 45 miles south of Houston at 1004 South Velasco Street in Angleton, Texas. The facility consists of three buildings equipped with offices, R&D laboratories, cGMP production area, documentation room, shipping and receiving, controlled storage areas and an animal research laboratory.

Cutting Edge


ITG has a variety of radioanalytical counting equipment including alpha, beta, and gamma counters. Most of the work with radiopharmaceuticals is done using NaI well crystals which we have coupled to ultichannel analyzers and sample changers. We also have several Ge crystals for high resolution gamma spectroscopy plus liquid scintillation capabilities to work with beta-emitting radionuclides.
We Work With These


Got a Project? Let's Schedule An Appointment

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Melbourne (Australia) – 27 February 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.
In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities. A key driver for the acquisition is to enable Telix to bring select aspects of its development programs in-house, with the goal of reducing cost and time to achieve technical milestones.
The acquisition will also expand Telix’s U.S. manufacturing footprint with a site that includes a GMP1 clean room and production infrastructure suitable for clinical use. The site also has extensive capacity to process a wide variety of therapeutic isotopes used in Telix’s development portfolio.